Aditya Birla Sun LifePharmaVery High Risk

Aditya Birla Sun Life Pharma Fund - Regular Plan - Growth

Current NAV₹27.88as of 30/5/2026

AUM3852.00 Cr

AUM

3852.00 Cr

Expense Ratio

1.95%

Min SIP

₹500

Min Lumpsum

₹1000

Launch Date

27 July 2009

Exit Load

Nil

Riskometer

LowModerateHighVery High

Risk Level: Very High

Volatility: 16.94 | Sharpe Ratio: 0.01

Fund Manager & Key Metrics

Fund ManagerMahesh Patil(3.5 years yrs)

Volatility16.94

Sharpe Ratio0.01

Portfolio Turnover63%

BenchmarkNifty Pharma TRI

Holdings Date25/5/2026

Asset Allocation

Equity: 96.00% | T-Bills: 4.00%

Investment Objective

Aims to provide capital appreciation by investing in Pharma securities

Top Holdings

As of 25-May-2026

1. Sun Pharmaceutical Industries Ltd.20.5%

2. Dr. Reddy's Laboratories Ltd.12.8%

3. Cipla Ltd.10.4%

4. Divi's Laboratories Ltd.9.8%

5. Torrent Pharmaceuticals Ltd.7.2%

6. Aurobindo Pharma Ltd.5.8%

7. Alkem Laboratories Ltd.5.2%

8. Lupin Ltd.4.9%

9. Ipca Laboratories Ltd.3.8%

10. Mankind Pharma Ltd.3.5%

Overview

Aditya Birla Sun Life Pharma Fund - Regular Plan - Growth – Poora parichay aur strategy

Aditya Birla Sun Life Pharma Fund - Regular Plan - Growth ek equity mutual fund hai jo ki primarily pharma sector mein invest karta hai. Iska objective hai long-term capital appreciation. Yeh fund un investors ke liye suitable hai jo high growth potential aur sector-specific risk ko samajhte hain. Fund ka investment style growth-oriented hai, jo ki high-quality pharmaceutical companies mein focus karta hai. Agar aap long-term wealth creation ke liye soch rahe hain, toh yeh fund aapke liye ek accha option ho sakta hai.

Performance & Analysis

Aditya Birla Sun Life Pharma Fund - Regular Plan - Growth ke returns – 1, 3, 5 saal ke aankde

Chaliye, ab hum Aditya Birla Sun Life Pharma Fund - Regular Plan - Growth ke returns par nazar daalte hain. Is fund ne apne benchmark, Nifty Pharma TRI, ke mukable kaise perform kiya hai, ye dekhte hain.

Time Period	Fund Returns (%)	Benchmark Returns (%)
1 Year	5.64%	Data not available
3 Years	6.75%	Data not available
5 Years	5.87%	Data not available

Yeh returns 1 saal, 3 saal aur 5 saal ke liye kaafi consistent hain, lekin volatility ko bhi dhyan mein rakhna zaroori hai. Mahesh Patil, jo ki fund manager hain, in returns ke peeche kaafi important role play karte hain. Unhone is fund ko actively manage kiya hai, jisse ki investors ko acha return mil sake. Overall, agar aap ek long-term investor hain, toh yeh fund aapko steady growth provide kar sakta hai, par risk ko samajhkar nivesh karein.

Aditya Birla Sun Life Pharma Fund - Regular Plan - Growth top holdings and portfolio allocation

Is fund ki portfolio allocation kaafi interesting hai. Aditya Birla Sun Life Pharma Fund - Regular Plan - Growth ki top 5 holdings mein kuch leading pharmaceutical companies hain: 1. Sun Pharmaceutical Industries Ltd. - 20.5% 2. Dr. Reddy's Laboratories Ltd. - 12.8% 3. Cipla Ltd. - 10.4% 4. Divi's Laboratories Ltd. - 9.8% 5. Torrent Pharmaceuticals Ltd. - 7.2% Fund ka overall strategy yeh hai ki wo top-quality companies mein invest karein jo ki long-term growth potential rakhti hain. Is tarah ki sector allocation se yeh fund apne investors ko sustainable growth ka mauka deta hai. Agar aap pharma sector ki growth ko samajhte hain, toh yeh fund aapke portfolio ke liye accha addition ho sakta hai.

Aditya Birla Sun Life Pharma Fund - Regular Plan - Growth riskometer and downside risk

Aditya Birla Sun Life Pharma Fund - Regular Plan - Growth ka riskometer "Very High" hai, matlab yeh fund high volatility ke saath aata hai. Yeh fund un investors ke liye suitable hai jo risk lene ke liye tayyar hain aur long-term investment horizon rakhte hain. Agar aap conservative investor hain, toh shayad yeh fund aapke liye nahi hai. Sharpe ratio ki data available nahi hai, lekin yeh fund market volatility ke liye kaafi sensitive hai. Isliye, agar aap is fund mein nivesh kar rahe hain, toh risk ko samajhna aur manage karna bahut zaroori hai. Risks ko ache se samajhkar hi aap is fund se maximum benefit le sakte hain.

Who Should Invest?

Aditya Birla Sun Life Pharma Fund - Regular Plan - Growth future outlook for long term investors

Aditya Birla Sun Life Pharma Fund - Regular Plan - Growth ka future outlook kaafi promising lagta hai. Pharma sector mehsoos kar raha hai growth opportunities, especially healthcare demands ke badhte trend aur innovation ki wajah se. Yeh fund historically bhi pharma stocks mein achi performance de chuka hai, jo ki long-term investors ke liye ek positive sign hai. Is fund ka sector exposure aapko long-term wealth creation mein madadgar ho sakta hai. Lekin, aapko market trends aur macroeconomic factors par nazar rakhni hogi. Updated in May 2026, yeh fund stability aur growth ke liye kaafi options provide karta hai. Long-term investors jo SIP investing ke zariye diversify karna chahte hain, unhe yeh fund consider karna chahiye.

Pros & Cons

Pros:
- High growth potential in the pharma sector.
- Strong portfolio with reputed companies.
- Managed by experienced fund manager.
- Suitable for long-term investors.
Cons:
- Very high risk level.
- Expense ratio of 1.95% is relatively high.
- Market volatility may affect returns.

Frequently Asked Questions

common questions about Aditya Birla Sun Life Pharma Fund - Regular Plan - Growth

1. Aditya Birla Sun Life Pharma Fund - Regular Plan - Growth kya hai?

Aditya Birla Sun Life Pharma Fund - Regular Plan - Growth ek equity mutual fund hai jo ki pharma sector mein invest karta hai, aimed at long-term capital appreciation.

2. Kya mujhe SIP ke zariye Aditya Birla Sun Life Pharma Fund mein nivesh karna chahiye?

Haan, SIP ke zariye aap is fund mein regular nivesh karke market volatility se bach sakte hain, jo long-term investing mein beneficial ho sakta hai.

3. Is fund mein nivesh karne se mujhe tax benefits mil sakte hain?

Haan, agar aap 3 saal se zyada is fund mein nivesh rakhte hain, toh aapko long-term capital gains ke tax benefits mil sakte hain, lekin aapko apne financial advisor se consult karna chahiye.

Returns

Period	Fund Return (%)	Benchmark (Nifty Pharma TRI) (%)
1 Year	5.64%	—
3 Years	6.75%	—
5 Years	5.87%	—
Since Launch	6.28%	—

SIP Calculator

SIP / Lumpsum Calculator

Monthly SIP Amount (₹)

SIP Period (Years)

Hold Period After SIP (Years)

Annual Step-Up (%)

Return Scenario

Based on fund's 3Y return of 6.8%

Invested: ₹956k

Gains: ₹3935k

Total Invested

₹956245.48

Total Returns

+ ₹3934887.50

Maturity Value

₹4891132.97

SIP of ₹5000 for 10 years (stepping up 10% annually), then held for 20 years at 6.8% p.a.

*Projected returns are for illustration only. Past performance does not guarantee future returns.

Similar Funds

Related Funds in Pharma

Old Bridge Mutual Fund Pharma Fund - Regular Plan - Growth Groww Mutual Fund Pharma Fund - Regular Plan - Growth Quantum Mutual Fund Pharma Fund - Regular Plan - Growth Sundaram Mutual Fund Pharma Fund - Regular Plan - Growth Bandhan Mutual Fund Pharma Fund - Regular Plan - Growth

Compare with Alternatives

Disclaimer: Mutual fund investments are subject to market risks. Please read all scheme‑related documents carefully before investing. Past performance does not guarantee future returns. The content on this page is for educational purposes only.